vs

Side-by-side financial comparison of ONESPAWORLD HOLDINGS Ltd (OSW) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

ONESPAWORLD HOLDINGS Ltd is the larger business by last-quarter revenue ($242.1M vs $127.1M, roughly 1.9× Zai Lab Ltd). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs 11.5%). ONESPAWORLD HOLDINGS Ltd produced more free cash flow last quarter ($14.9M vs $-26.7M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs 7.1%).

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

OSW vs ZLAB — Head-to-Head

Bigger by revenue
OSW
OSW
1.9× larger
OSW
$242.1M
$127.1M
ZLAB
Growing faster (revenue YoY)
ZLAB
ZLAB
+5.6% gap
ZLAB
17.1%
11.5%
OSW
More free cash flow
OSW
OSW
$41.6M more FCF
OSW
$14.9M
$-26.7M
ZLAB
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
7.1%
OSW

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OSW
OSW
ZLAB
ZLAB
Revenue
$242.1M
$127.1M
Net Profit
$12.1M
Gross Margin
51.0%
Operating Margin
6.8%
-54.6%
Net Margin
5.0%
Revenue YoY
11.5%
17.1%
Net Profit YoY
-16.2%
EPS (diluted)
$0.12
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OSW
OSW
ZLAB
ZLAB
Q4 25
$242.1M
$127.1M
Q3 25
$258.5M
$115.4M
Q2 25
$240.7M
$109.1M
Q1 25
$219.6M
$105.7M
Q4 24
$217.2M
$108.5M
Q3 24
$241.7M
$101.8M
Q2 24
$224.9M
$100.1M
Q1 24
$211.2M
$87.1M
Net Profit
OSW
OSW
ZLAB
ZLAB
Q4 25
$12.1M
Q3 25
$24.3M
$-36.0M
Q2 25
$19.9M
$-40.7M
Q1 25
$15.3M
$-48.4M
Q4 24
$14.4M
Q3 24
$21.6M
$-41.7M
Q2 24
$15.8M
$-80.3M
Q1 24
$21.2M
$-53.5M
Gross Margin
OSW
OSW
ZLAB
ZLAB
Q4 25
51.0%
Q3 25
59.5%
Q2 25
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
64.9%
Q1 24
61.4%
Operating Margin
OSW
OSW
ZLAB
ZLAB
Q4 25
6.8%
-54.6%
Q3 25
10.2%
-42.3%
Q2 25
9.2%
-50.3%
Q1 25
7.7%
-53.3%
Q4 24
7.9%
-62.6%
Q3 24
10.3%
-66.6%
Q2 24
8.4%
-76.0%
Q1 24
8.0%
-80.7%
Net Margin
OSW
OSW
ZLAB
ZLAB
Q4 25
5.0%
Q3 25
9.4%
-31.2%
Q2 25
8.3%
-37.3%
Q1 25
7.0%
-45.8%
Q4 24
6.6%
Q3 24
8.9%
-40.9%
Q2 24
7.0%
-80.2%
Q1 24
10.0%
-61.4%
EPS (diluted)
OSW
OSW
ZLAB
ZLAB
Q4 25
$0.12
$-0.05
Q3 25
$0.23
$-0.03
Q2 25
$0.19
$-0.04
Q1 25
$0.15
$-0.04
Q4 24
$0.13
$-0.09
Q3 24
$0.20
$-0.04
Q2 24
$0.15
$-0.08
Q1 24
$0.21
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OSW
OSW
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$16.3M
$689.6M
Total DebtLower is stronger
$84.0M
Stockholders' EquityBook value
$542.6M
$715.5M
Total Assets
$707.1M
$1.2B
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OSW
OSW
ZLAB
ZLAB
Q4 25
$16.3M
$689.6M
Q3 25
$29.6M
$717.2M
Q2 25
$35.0M
$732.2M
Q1 25
$22.6M
$757.3M
Q4 24
$57.4M
$779.7M
Q3 24
$48.8M
$616.1M
Q2 24
$62.5M
$630.0M
Q1 24
$65.4M
$650.8M
Total Debt
OSW
OSW
ZLAB
ZLAB
Q4 25
$84.0M
Q3 25
$85.2M
Q2 25
$96.2M
Q1 25
$97.4M
Q4 24
$98.6M
Q3 24
$98.7M
Q2 24
$123.8M
Q1 24
$138.6M
Stockholders' Equity
OSW
OSW
ZLAB
ZLAB
Q4 25
$542.6M
$715.5M
Q3 25
$552.8M
$759.9M
Q2 25
$548.3M
$791.7M
Q1 25
$530.6M
$810.8M
Q4 24
$554.5M
$840.9M
Q3 24
$540.1M
$667.7M
Q2 24
$532.7M
$704.2M
Q1 24
$515.5M
$762.2M
Total Assets
OSW
OSW
ZLAB
ZLAB
Q4 25
$707.1M
$1.2B
Q3 25
$732.6M
$1.2B
Q2 25
$731.8M
$1.2B
Q1 25
$708.7M
$1.2B
Q4 24
$746.4M
$1.2B
Q3 24
$734.0M
$985.3M
Q2 24
$756.8M
$987.4M
Q1 24
$763.6M
$988.4M
Debt / Equity
OSW
OSW
ZLAB
ZLAB
Q4 25
0.15×
Q3 25
0.15×
Q2 25
0.18×
Q1 25
0.18×
Q4 24
0.18×
Q3 24
0.18×
Q2 24
0.23×
Q1 24
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OSW
OSW
ZLAB
ZLAB
Operating Cash FlowLast quarter
$20.0M
$-26.0M
Free Cash FlowOCF − Capex
$14.9M
$-26.7M
FCF MarginFCF / Revenue
6.2%
-21.0%
Capex IntensityCapex / Revenue
2.1%
0.5%
Cash ConversionOCF / Net Profit
1.65×
TTM Free Cash FlowTrailing 4 quarters
$68.4M
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OSW
OSW
ZLAB
ZLAB
Q4 25
$20.0M
$-26.0M
Q3 25
$33.2M
$-32.0M
Q2 25
$20.3M
$-31.0M
Q1 25
$10.1M
$-61.7M
Q4 24
$16.6M
$-55.8M
Q3 24
$28.6M
$-26.8M
Q2 24
$18.7M
$-42.2M
Q1 24
$15.0M
$-90.1M
Free Cash Flow
OSW
OSW
ZLAB
ZLAB
Q4 25
$14.9M
$-26.7M
Q3 25
$27.6M
$-35.0M
Q2 25
$17.6M
$-33.9M
Q1 25
$8.4M
$-63.2M
Q4 24
$13.2M
$-58.4M
Q3 24
$27.5M
$-28.2M
Q2 24
$17.6M
$-42.9M
Q1 24
$13.7M
$-91.1M
FCF Margin
OSW
OSW
ZLAB
ZLAB
Q4 25
6.2%
-21.0%
Q3 25
10.7%
-30.4%
Q2 25
7.3%
-31.1%
Q1 25
3.8%
-59.9%
Q4 24
6.1%
-53.8%
Q3 24
11.4%
-27.7%
Q2 24
7.8%
-42.9%
Q1 24
6.5%
-104.5%
Capex Intensity
OSW
OSW
ZLAB
ZLAB
Q4 25
2.1%
0.5%
Q3 25
2.2%
2.6%
Q2 25
1.1%
2.6%
Q1 25
0.8%
1.5%
Q4 24
1.5%
2.4%
Q3 24
0.5%
1.3%
Q2 24
0.5%
0.7%
Q1 24
0.6%
1.1%
Cash Conversion
OSW
OSW
ZLAB
ZLAB
Q4 25
1.65×
Q3 25
1.36×
Q2 25
1.02×
Q1 25
0.66×
Q4 24
1.15×
Q3 24
1.33×
Q2 24
1.19×
Q1 24
0.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OSW
OSW

Services$197.3M82%
Products$44.8M18%

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons